Literature DB >> 10409825

Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system.

B N Dominy1, C L Brooks.   

Abstract

A protocol for the rapid energetic analysis of protein-ligand complexes has been developed. This protocol involves the generation of protein-ligand complex ensembles followed by an analysis of the binding free energy components. We apply this methodology toward understanding the origin of binding specificity within the human immunodeficiency virus/feline immunodeficiency virus (HIV/FIV) protease system, a model system for drug resistance studies. A distinct difference in the internal strain of an inhibitor within each protein environment clearly favors the HIV protease complex, as observed experimentally. Our analysis also predicts that residues within the S2-S3 pockets of the FIV protease active site are responsible for this strain. Close examination of the active site residue contributions to interaction energy and desolvation energy identifies specific amino acids that may also play a role in determining the binding preferences of these two enzymes. Proteins 1999;36:318-331. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409825     DOI: 10.1002/(sici)1097-0134(19990815)36:3<318::aid-prot6>3.0.co;2-k

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  5 in total

1.  Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Authors:  Mark D Shenderovich; Ron M Kagan; Peter N R Heseltine; Kal Ramnarayan
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

2.  Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.

Authors:  Y C Lin; Z Beck; T Lee; V D Le; G M Morris; A J Olson; C H Wong; J H Elder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  NMR and MD investigations of human galectin-1/oligosaccharide complexes.

Authors:  Christophe Meynier; Mikael Feracci; Marion Espeli; Florence Chaspoul; Philippe Gallice; Claudine Schiff; Françoise Guerlesquin; Philippe Roche
Journal:  Biophys J       Date:  2009-12-16       Impact factor: 4.033

4.  Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.

Authors:  Ying-Chuan Lin; Zachary Beck; Garrett M Morris; Arthur J Olson; John H Elder
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.

Authors:  Serdar Durdagi; Trevor Randall; Henry J Duff; Adam Chamberlin; Sergei Y Noskov
Journal:  BMC Pharmacol Toxicol       Date:  2014-03-08       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.